Spectral Molecular Imaging Readies IDE For Melanoma Detection Trial
This article was originally published in The Gray Sheet
Executive Summary
Spectral Molecular Imaging will submit an investigational device exemption application to FDA within three months for its SkinSpect system to aid early melanoma detection.
You may also be interested in...
Mela Sciences' MelaFind goes to panel
FDA's General and Plastic Surgery Devices advisory panel will meet Nov. 18 to discuss a pre-market approval application for Mela Sciences' non-invasive computer vision system to aid in the detection of melanoma. The computer-controlled multi-spectral dermoscope uses light to image skin through a thin layer of liquid, making lesions under the skin surface visible to the eye; a digital camera inside the probe captures images and differentiates lesions for melanoma risk using pattern recognition software. The panel review was postponed from Aug. 26 to allow FDA more time to arrange the meeting (1"The Gray Sheet" July 26, 2010)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.